Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Aggressive Non-Hodgkin's Lymphoma”

114 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 114 results

Testing effectiveness (Phase 2)Study completedNCT00783367
What this trial is testing

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Who this might be right for
Follicular LymphomaMarginal Zone B-Cell LymphomaMALT Lymphoma+4 more
Abramson Cancer Center at Penn Medicine 50
Testing effectiveness (Phase 2)Study completedNCT00789776
What this trial is testing

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAggressive Non-Hodgkin Lymphoma+13 more
Fred Hutchinson Cancer Center 41
Testing effectiveness (Phase 2)Looking for participantsNCT03938987
What this trial is testing

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Relapsed Non Hodgkin LymphomaRelapsed Adult ALLRelapsed Pediatric ALL
University of Alberta 63
Testing effectiveness (Phase 2)Study completedNCT00702052
What this trial is testing

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

Who this might be right for
Lymphoma, Mantle- Cell
Novartis Pharmaceuticals 58
Early research (Phase 1)Ended earlyNCT02663518
What this trial is testing

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Who this might be right for
Hematologic MalignanciesSolid Tumor
Pfizer 249
Early research (Phase 1)Active Not RecruitingNCT02651662
What this trial is testing

Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Lymphoma
Regeneron Pharmaceuticals 105
Testing effectiveness (Phase 2)Active Not RecruitingNCT04531046
What this trial is testing

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

Who this might be right for
B-Cell Lymphoma RefractoryB-cell Lymphoma Recurrent
The Lymphoma Academic Research Organisation 62
Early research (Phase 1)Study completedNCT03061188
What this trial is testing

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Who this might be right for
Advanced Solid NeoplasmAggressive Non-Hodgkin LymphomaRecurrent Solid Neoplasm+3 more
Northwestern University 15
Large-scale testing (Phase 3)Study completedNCT02910063
What this trial is testing

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

Who this might be right for
B-Cell Non Hodgkin Lymphoma
Amgen 41
Early research (Phase 1)Looking for participantsNCT05412290
What this trial is testing

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Who this might be right for
B Cell LymphomaAggressive LymphomaDiffuse Large B Cell Lymphoma+3 more
Washington University School of Medicine 15
Testing effectiveness (Phase 2)UnknownNCT01653067
What this trial is testing

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Mathias Witzens-Harig 88
Testing effectiveness (Phase 2)Looking for participantsNCT06834373
What this trial is testing

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Who this might be right for
Large B-Cell Lymphoma With IRF4 RearrangementRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent ALK-Positive Large B-Cell Lymphoma+28 more
Mayo Clinic 41
Testing effectiveness (Phase 2)Looking for participantsNCT06244368
What this trial is testing

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Who this might be right for
Peripheral T Cell LymphomaDiffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 115
Testing effectiveness (Phase 2)Ended earlyNCT00367497
What this trial is testing

Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Keio University 5
Large-scale testing (Phase 3)Study completedNCT00075478
What this trial is testing

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Who this might be right for
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionAggressive Non-Hodgkin Lymphoma+10 more
Fred Hutchinson Cancer Center 87
Early research (Phase 1)Study completedNCT01231919
What this trial is testing

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more
National Cancer Institute (NCI) 45
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Study completedNCT02750670
What this trial is testing

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin's
University Health Network, Toronto 30
Large-scale testing (Phase 3)Study completedNCT03575351
What this trial is testing

Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 184
Testing effectiveness (Phase 2)UnknownNCT04553393
What this trial is testing

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Who this might be right for
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Chinese PLA General Hospital 80
Load More Results